Melinda Yin

Dr. Melinda Yin

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
BKBrianna M. Krusen
Brianna M. Krusen
PGPhyllis A. Gimotty
Phyllis A. Gimotty
GDGreg Donahue
Greg Donahue
JTJacob E. Till
Jacob E. Till
MYMelinda Yin
Melinda Yin
KZKenneth S. Zaret
Kenneth S. Zaret
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is typically detected too late for useful therapeutic interventions; hence, we sought blood biomarkers to detect early-stage disease. Experimental Design: Using mass spectrometry and ELISA on plasma pools from the University of Pennsylvania (Penn) and the Mayo Clinic (Mayo), we identified aminopeptidase N (ANPEP) and polymeric immunoglobulin receptor (PIGR) as increased in early-stage (stage I/II) PDAC plasma compared with controls. We tested ANPEP and PIGR, along with prior data for thrombospondin 2 (THBS2) and carbohydrate antigen 19-9 (CA19-9), in retrospective phase II studies using separate cohorts of PDAC plasmas at different stages versus healthy or nonmalignant disease controls (DC) from Penn (n = 135) and Mayo (n = 537). Results: Comparing healthy controls with stage I/II PDAC, we obtained area under the receiver-operating characteristic curves (AUC) of 0.78 [95% confidence interval (CI), 0.68–0.86]/0.80 (95% CI, 0.74–0.85; ANPEP) and 0.81 (95% CI, 0.70–0.88)/0.86 (95% CI, 0.82–0.90; PIGR) for the Penn/Mayo phase II studies, respectively. In multivariable models, CA19-9/THBS2/ANPEP, CA19-9/THBS2/PIGR, and CA19-9/THBS2/ANPEP/PIGR elicited AUC of 0.94 to 0.96 for Penn and 0.97 for Mayo. Notably, the four-marker panel elicited AUC of 0.87 for the Mayo stage I/II versus DC and 0.91 for stages I to IV versus DC. At a specificity of 95%, a plasma biomarker panel composed of CA19-9 (≥35 U/mL), THBS2 (≥42 ng/mL), ANPEP (≥2,995 ng/mL), and PIGR (≥1,800 ng/mL) yielded a sensitivity of 91.9% for PDAC stages I to IV and 87.5% for PDAC stage I/II. Conclusions: Adding ANPEP and PIGR to a plasma biomarker panel of CA19-9 and THBS2 enhances the detection of early-stage PDAC when comparing cancer versus healthy or nonmalignant DC. Given the concordance of our data in two retrospective phase II studies, assessments in prediagnostic cases are warranted.

31 January 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
JTJacob E. Till
Jacob E. Till
NSNicholas J. Seewald
Nicholas J. Seewald
ZYZachariya Yazdani
Zachariya Yazdani
ZWZhuoyang Wang
Zhuoyang Wang
DBDominique Ballinger
Dominique Ballinger
ECErica L. Carpenter
Erica L. Carpenter
Purpose: Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown. Experimental Design: We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn prior to initial resection (baseline) and at the time of the first postradiotherapy MRI. We performed ccfDNA methylation deconvolution to determine cellular sources of ccfDNA. ELISA was performed to detect citrullinated histone 3 (citH3), a marker of neutrophil extracellular traps (NET). Multiplex proteomic analysis was used to measure soluble inflammatory proteins. Results: We found that neutrophils contributed the highest proportion of prognostic ccfDNA. The percentage of ccfDNA derived from neutrophils was correlated with total [ccfDNA] but only in patients receiving preoperative corticosteroids. At baseline and on therapy, [citH3] was significantly higher in the plasma of patients with GBM receiving corticosteroids compared with corticosteroid-naïve GBM or no-cancer controls. Unsupervised hierarchical clustering of ccfDNA methylation patterns yielded two clusters, with one enriched for patients with the NETosis phenotype and who received corticosteroids. Unsupervised clustering of circulating inflammatory proteins yielded similar results. Conclusions: These data suggest neutrophil-mediated NETosis is the dominant source of prognostic ccfDNA in patients with GBM and may be associated with glucocorticoid exposure. If further studies show that pharmacological inhibition of NETosis can mitigate the deleterious effects of corticosteroids, these plasma markers will have important clinical utility as noninvasive correlative biomarkers.

1 September 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
ECErica L. Carpenter
Erica L. Carpenter
JTJacob E. Till
Jacob E. Till
DBDominique Ballinger
Dominique Ballinger
CMCamilla Macia
Camilla Macia
CLCarlos Leche
Carlos Leche
SBStephen Joseph Bagley
Stephen Joseph Bagley
PURPOSE: Because of tumor heterogeneity and sampling error, next-generation sequencing (NGS) of glioblastoma (GBM) tumors may provide an incomplete picture of the somatic mutational landscape. We hypothesized that simultaneous targeted NGS of matched tumor tissue and cerebrospinal fluid (CSF), obtained during craniotomy for resection of GBM, would lead to identification of clinically relevant variants not detected by tissue NGS alone. METHODS: We enrolled 50 patients undergoing resection of newly diagnosed (n = 15) or recurrent (n = 35) GBM. CSF was collected intraoperatively via the subarachnoid space (n = 25) or lateral ventricle (n = 25) and assayed by NGS using a hybrid capture liquid biopsy panel. Matched tumor tissue also underwent large panel hybrid capture NGS testing. RESULTS: CSF samples from 28 of 50 patients (56%) passed quality control metrics. At least one CSF variant was detected in 25 of 28 patients (89%), and 22 of 28 patients had matched tissue sequencing results available. In these 22 patients (primary analysis cohort), the median number of variants detected in CSF was higher than in tissue (3 v 2 variants, respectively; P = .0035), and 15 of 22 patients (68%) had ≥1 CSF variant not detected in matched tissue, including clinically relevant alterations in EGFR , PMS2 , PIK3CA , and TP53 . CONCLUSION: The addition of intraoperatively acquired CSF liquid biopsy to tissue NGS in patients with GBM may improve detection of clinically relevant variants, potentially improving selection of patients for clinical trials.


6 March 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
SGSophia Giliberto
Sophia Giliberto
KAKenny Ablordeppey
Kenny Ablordeppey
JGJacob Goldman
Jacob Goldman
MYMelinda Yin
Melinda Yin
RCRahul Chowdhury
Rahul Chowdhury
SBStephen Joseph Bagley
Stephen Joseph Bagley
Background: Noninvasive biomarkers for the detection and monitoring of glioblastoma (GBM) are needed to improve clinical outcomes for patients. The objective of this pilot study was to evaluate the expression of a panel of 48 pre-selected microRNAs (miRNAs) in plasma specimens from GBM patients versus healthy controls to identify candidate miRNA biomarkers for noninvasive diagnosis of GBM. Methods: Selection of candidate miRNA biomarkers was based on a comprehensive literature review and data mining. RNA was extracted from plasma samples obtained prior to resection from patients with GBM (n = 30) and age- and sex-matched healthy controls (n = 30), as well as from matched FFPE GBM tissue samples when available (n = 3). Expression levels of 48 miRNAs were assessed in all samples, and expression data was processed using proprietary software to generate potential biomarkers and train linear classifiers. Results: Overall miRNA expression patterns were similar between matched plasma and FFPE tumor tissues in patients with GBM. miRNA levels were examined in pairs to determine the ratio between two miRNAs, which served to normalize the data. The top five miRNA pairs for distinguishing between GBM and healthy control plasma included miR-17-5p/miR-19b-3p (AUC 0.93, 95% CI = 0.870, 0.970), miR-20a-5p/miR-19b-3p (AUC 0.93, 95% CI = 0.870, 0.970), miR-93-5p/miR-92a-3p (AUC 0.92, 95% CI = 0.875, 0.965), miR-17-5p/miR-92a-3p (AUC 0.91, 95% CI = 0.865, 0.955), and miR-93-5p/miR-19b-3p (AUC 0.90, 95% CI = 0.850, 0.950). For the development of a multi-biomarker combination classifier consisting of up to three miRNA pair biomarkers, miRNA pairs with an AUC ≥ 0.8 were selected to build equal-weight linear classifiers. All possible combinations of three high-performing miRNA pairs were tested across the 60 samples. The top classifier (miR-20a-5p/miR-451a, miR-582-5p/miR-222-3p, and miR-17-5p/miR-222-3p) achieved an AUC value of 0.992, sensitivity of 0.93, specificity of 1, and accuracy of 0.97. Conclusions: These findings support the continued development of a plasma-based miRNA molecular diagnostic approach for the detection of GBM. The strong discriminatory performance observed in this study, including high AUC values, highlights the potential of circulating miRNA signatures as a minimally invasive diagnostic tool. As a pilot analysis, this work establishes a foundation for future prospective studies in larger, independent cohorts—including relevant disease control populations—to further define clinical performance, specificity, and utility in diagnostic and monitoring settings. Collectively, these results represent an important step toward the translation of plasma-based miRNA profiling into clinical application for GBM.

1 April 2025
Verified
Other
Open access
JTJacob E. Till
Jacob E. Till
NSNicholas J. Seewald
Nicholas J. Seewald
ZYZachariya Yazdani
Zachariya Yazdani
ZWZhuoyang Wang
Zhuoyang Wang
DBDominique Ballinger
Dominique Ballinger
ECErica L. Carpenter
Erica L. Carpenter
Supplemental Figure 1. Patients and assays Supplemental Figure 2. Survival analysis at baseline and post-radiation Supplemental Figure 3. Correlative analysis of all ccfDNA deconvolution subsets with [ccfDNA]. Supplemental Figure 4. Analysis of % neutrophil tissue DNA and pre-operative steroids. Supplemental Figure 5. Correlative analysis of all ccfDNA deconvolution subsets with [citH3]. Supplemental Figure 6. Analysis of % neutrophil tissue DNA and [citH3]. Supplemental Figure 7. Analysis of [citH3], pre-operative steroid dose, and tumor volume. Supplemental Figure 8. Analysis of % neutrophil ccfDNA by steroid exposure. Supplemental Figure 9. Percent neutrophil ccfDNA and [citH3] at time of first post-radiation MRI. Supplemental Figure 10. Analysis of % neutrophil ccfDNA and total [ccfDNA] by steroid exposure. Supplemental Figure 11. Molecular sub-type analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results. Supplemental Figure 12. Unsupervised clustering of tissue DNA methylation data, differential methylation, and pathway analysis. Supplemental Figure 13. Analysis of Clusters 1 and 2 from tissue DNA differential methylation analysis. Supplemental Figure 14. Analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results.